Karolinska Development and Kurma Biofund Sign Strategic Agreement to Identify Life Science Oppurtunities in Europe

Karolinska Development AB, a Solna, Sweden-based life science investor, and Kurma Biofund, a venture capital fund based in Paris, France, have entered into a strategic partnership.
The purpose of the deal is to identify early stage co-investment opportunities in the life science sector in the Nordic region and other selected parts of Europe.
Since its inception in 2003, Karolinska Development has built a portfolio of some 40 companies.
Kurma Biofund, which is dedicated to innovations in Life Sciences and Healthcare, has closed a first round of financing of €50m on the 24th November 2009.

Join the discussion